logo-loader

Redhill Biopharma's Opaganib 'one of most advanced, novel investigational drugs for Covid-19'

Published: 07:24 09 Oct 2020 EDT

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg talks to Proactive London about their operations, which include working towards a remedy for Covid-19 with Opaganib.

Goldberg describes the drug as 'one of most advantaged, novel investigational Covid-19 drugs'. Opaganib is orally-taken, which targets a host cell component and is unaffected by viral mutation.

Goldberg explains why the drug is unique with its 'mechanism for action', first being that it is anti-viral and secondly, that it is anti-inflammatory'.

The medicine is already available in Israel on a 'compassionate' use basis, which has proved successful for five patients who had 'moderate to severe' Covid-19 symptoms.

RedHill Biopharma shows strong inhibition by opaganib of the coronavirus...

RedHill Biopharma (NASDAQ:RDHL) Ltd (NASDAQ:RDHL) chief business officer Guy Goldberg caught up with Proactive New York to speak on results of its new preclinical study, which he says demonstrated strong inhibition by its investigational oral pill opaganib of the coronavirus Delta variant...

on 27/8/21